trending Market Intelligence /marketintelligence/en/news-insights/trending/bj0ywxiubek2qbybrcuyeg2 content esgSubNav
In This List

Novus Therapeutics starts common stock offering

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Novus Therapeutics starts common stock offering

Irvine, Calif.- based Novus Therapeutics Inc. started an underwritten public offering of 6 million common shares.

The pharmaceutical company will give underwriters a 30-day option to buy up to an additional 900,000 shares.

Net proceeds will be used to fund two phase 2 clinical trials for drug OP-02 to treat and prevent otitis media, an inflammation of the middle ear.

Piper Jaffray & Co. is sole book-running manager for the offering, with Ladenburg Thalmann & Co. Inc. and LifeSci Capital LLC as co-managers.

Novus Therapeutics develops products for ear, nose and throat diseases.